Affymetrix, Inc. v. Illumina, Inc.

I'll research this case thoroughly using web searches to verify the details.

Let me research the specific patents and procedural details.

Below is a verified overview and background of Affymetrix, Inc. v. Illumina, Inc., No. 1:04-cv-00901-JJF (D. Del.), building on the existing summary. I flag points that are well-sourced versus those I could not fully verify.

Parties, technology, and accused products

Both parties are publicly traded operating companies in the genomics-tools industry — this is not an NPE/PAE case. Affymetrix, Inc. (Santa Clara, CA; a Delaware corporation) was the pioneer of the DNA microarray/"gene chip," commercializing high-density oligonucleotide arrays built on its proprietary VLSIPS (Very Large Scale Immobilized Polymer Synthesis) platform, spun out of Affymax Research Institute; its chairman/CEO was inventor Dr. Stephen P.A. Fodor. Illumina, Inc. (San Diego, CA; also a Delaware corporation) developed and sold next-generation genetic-analysis tools, chiefly its proprietary BeadArray technology (Array Matrix and BeadChip products) used in genomics and pharma research; CEO Jay Flatley. Affymetrix's global IP litigation was run unusually by an in-house trial team led by GC Barbara Caulfield and Michael Malacek (a notable staffing feature of the case), with Morris, Nichols, Arsht & Tunnell (Jack B. Blumenfeld, Maryellen Noreika) as local counsel; Illumina was represented by Kirkland & Ellis (Robert G. Krupka, Mark A. Pals, Marcus E. Sernel) with Morris James as local counsel.

The accused technology was Illumina's BeadArray platform — its arrays, assays (including GoldenGate and Infinium I), expression assays, scanners, and related software. The damages phase covered products commercialized 2002 through 2005. A later, related October 2007 wave of Affymetrix suits (D. Del., England, and Germany) expanded the target set to additional BeadArray patents and to Solexa sequencing technology, which Illumina had acquired in January 2007 (per Drug Discovery News/Foley Hoag reprint, Nov. 2007).

Patents at issue

The July 26, 2004 complaint asserted six patents; Affymetrix dropped one (the '887) in March 2006, leaving five patents-in-suit construed at Markman:

• US 5,795,716 — "Computer-aided visualization and analysis system for sequence evaluation": a computer system/method for determining unknown bases by analyzing fluorescent probe intensities and generating "base calls" (the software/data-analysis patent).
• US 6,355,432 — "Products for detecting nucleic acids": bead/particle arrays in which beads are "coded with an encoding system" separate from the binding polymer (squarely aimed at bead-array formats).
• US 6,646,243 — "Nucleic acid reading and analysis system": an apparatus claim covering a substrate with ≥1,000 different beads/particles (area <1 cm²), a laser excitation source, a fluorescence detector, and a data-collection system.
• US 5,545,531 — "Methods for making a device for concurrently processing multiple biological chip assays": methods of fabricating devices for parallel chip assays (originally assigned to Affymax).
• US 6,399,365 — a related method patent directed to making/using a device for concurrently processing multiple biological chip assays (I could not fully verify the exact title wording via primary sources).
• US 6,607,887 — asserted in the complaint but dropped from suit in March 2006, with a stipulated order dismissing the '887 counts filed June 23, 2006 (D.I. 266). I could not independently verify the '887's title.

Procedural posture, venue, and why the case is notable

Affymetrix filed on July 26, 2004 in the U.S. District Court for the District of Delaware, assigned to Judge Joseph J. Farnan, Jr. (No. 04-901-JJF). Venue mattered because both companies are Delaware corporations, and Judge Farnan had already tried the earlier Oxford Gene Technology v. Affymetrix microarray case (99-348-JJF) in the same court — Delaware was the established forum for this technology fight. Illumina counterclaimed for declaratory judgment of non-infringement, invalidity, and unenforceability, and on February 15, 2006 the court allowed an amended answer adding inequitable conduct as to each patent, Sherman Act antitrust violations, and unclean hands (per Illumina's Aug. 17, 2006 press release). The court bifurcated the case into three phases: (1) infringement and damages; (2) validity/enforceability (inequitable conduct); and (3) willfulness/antitrust. Key rulings: a standing/ownership opinion rejecting Illumina's challenge to Affymetrix's title to the '716 (446 F. Supp. 2d 292, Aug. 16, 2006) and a Markman order the same day (446 F. Supp. 2d 277), which adopted Illumina's narrower reading of the '432's "encoding system" limitation — leading analysts to predict Illumina might escape the '432 (Duke Law thesis tracking the litigation). Phase 1 was tried beginning March 5, 2007; on March 12–13, 2007 the jury found Illumina infringed (and induced infringement of) all five patents, rejected Affymetrix's lost-profits claim, and awarded $16.7 million at a 15% royalty for 2002–2005 sales. Illumina filed Rule 50(a) JMOL motions (D.I. 411, Mar. 8, 2007) and signaled an appeal, while parallel USPTO ex parte reexaminations were granted on several of the patents-in-suit (GenomeWeb reported reexams of the '432 and '243, and separately the '531 and '716), alongside a related patent interference in which Illumina was named senior party against Stanford's US 6,858,412, licensed to Affymetrix's ParAllele unit.

The case settled on January 10, 2008: Illumina agreed to pay Affymetrix $90 million without admitting liability; Affymetrix would dismiss all lawsuits (the 2004 Delaware case plus the October 2007 U.S./UK/Germany suits) with prejudice, Illumina would drop its counterclaims, and Affymetrix granted a perpetual covenant not to sue on Illumina's current products and evolutions (all fields except photolithography) plus a four-year covenant on future-technology products (AP, Jan. 10, 2008; BioCentury; Law.com "An Inside Job at Affymetrix"). The stipulated dismissal with prejudice was entered January 16, 2008, terminating the case — the $16.7M Phase 1 verdict was superseded by the settlement. The case is notable as a defining "gene chip" war between the two dominant microarray firms; as an operating-company patentee (not an NPE) enforcing a pioneering portfolio; as a $90M global resolution that reshaped the market and presaged Illumina's rise and Affymetrix's decline; as a template for triaged multi-phase patent trials (infringement first, then invalidity, then antitrust) that became common later; and as an early example of parallel USPTO administrative challenges (reexaminations, since IPRs did not exist pre-AIA) running alongside district-court litigation. One caveat: some granular details (e.g., the '887 and '365 titles, exact reexam request dates/outcomes, and the precise post-trial appeal disposition) are drawn from secondary sources and press releases rather than full PACER/docket review, and should be confirmed against the docket before being treated as definitive.

I'll research this case systematically across the docket, opinions, and press coverage.

Good foundation. Now let me dig into the Markman ruling, docket events, and the PTO reexaminations/interferences.

Let me nail down the docket history, counterclaims, and the PTO proceedings.

Affymetrix, Inc. v. Illumina, Inc., C.A. No. 04-901-JJF (D. Del.) — Chronology of Key Developments

Bottom line: This was a hard-fought, multi-phase microarray patent war that produced a plaintiff's jury verdict on infringement and $16.7M in back damages, but ended in a global, three-jurisdiction settlement ($90M, no admission of liability) before validity, enforceability, inequitable conduct, antitrust, willfulness, or injunction issues were ever tried — and before any appeal. No IPR/PGR ever figured in the case, because the AIA's IPR/PGR regime did not exist during the litigation (see §9).

---

1. Filing and initial pleadings (2004)

• 2004-07 (reported as July 2004): Affymetrix filed its complaint in the District of Delaware against Illumina, accusing Illumina's BeadArray products and services, including the Array Matrix and BeadChip products, of infringing six Affymetrix patents, and seeking unspecified monetary damages plus an injunction against sales of infringing products. (Illumina Form 10-K/10-Q disclosures; Illumina press release 2007-03-13: "In July 2004, Affymetrix brought this suit against Illumina in front of Judge Joseph J. Farnan.")
  • The five patents actually tried were US 5,545,531; 5,795,716; 6,355,432; 6,399,365; and 6,646,243.
  • The sixth patent in the case metadata, US 6,607,887, is almost certainly the one Affymetrix later withdrew (see §3) — I could not independently confirm the identity of the dropped patent; treat that mapping as probable, not proven.
• 2004-09 (September 2004): Illumina filed its answer and counterclaims, seeking declaratory judgments of non-infringement and invalidity, plus counterclaims against Affymetrix for unfair competition and interference with actual and prospective economic advantage. (Illumina 10-K/10-Q disclosures; GenomeWeb, 2007-03.)
• 2005-03-10: First substantive discovery exchange reflected on the docket — Illumina's objections/responses to Affymetrix's first set of document requests and interrogatories (D.I. 41, Notice of Service).
• 2005-07-28: The District of Delaware's own opinion index lists an opinion in this case dated 2005-07-28 (Judge Farnan). I was unable to retrieve the subject matter of that ruling from the sources reached; flagging it rather than characterizing it. (https://www.ded.uscourts.gov/opinion/affymetrix-inc-v-illumina-inc)

2. Escalation of the pleadings and the parallel PTO track (2005–2006)

• 2005-10 (October 2005): Illumina asked the USPTO to examine Affymetrix patents — the beginning of the reexamination track that ran in parallel to the litigation. (Instrument Business Outlook, 2007-03.)
• 2006-01 (January 2006): Illumina filed an amended response alleging inequitable conduct, specifically that Affymetrix "withheld material prior art" during prosecution — including the contention that Affymetrix knew of prior work by Russian/Yugoslavian molecular biologists and informaticists. (GenomeWeb, citing BioArray News 2006-01-10.)
• 2006-02-15: Court granted leave for Illumina's first amended answer and counterclaims, adding (i) inequitable conduct as to all six asserted patents, (ii) a Section 2 Sherman Act violation, and (iii) unclean hands. (Illumina 10-K FY2006; 10-Q Q1 2008.)
• 2006-02-06: Affymetrix letter to Judge Farnan (D.I. 205) seeking to move the Markman hearing from its scheduled 2006-03-08 date because fact discovery had been extended three weeks (to 2006-02-24) and "there are one or more depositions set for virtually every day between now and February 23," with at least eight depositions still unscheduled. Illumina did not agree to the postponement.

3. Narrowing the case; discovery and motion milestones (spring–summer 2006)

• 2006-03 (March 2006): Affymetrix notified Illumina it would drop one of the six patents and would assert additional claims of the remaining five. Illumina moved to preclude assertion of the new claims; that motion was still pending as of Illumina's FY2006 10-K.
• 2006-04-20: Markman hearing held before Judge Farnan. (Illumina 10-K.)
• 2006-06-30: Court dismissed the patent Affymetrix had sought to withdraw, leaving five patents in suit. (Illumina 10-K/10-Q.)
• 2006-06-30 (same date reported): Illumina's motion to dismiss Count 2 (the '716 patent) for lack of standing/subject-matter jurisdiction was denied: Affymetrix, Inc. v. Illumina, Inc., 446 F. Supp. 2d 292 (D. Del. 2006) (D.I. 234). The court rejected Illumina's argument that legal title to the '716 patent never passed from inventor Dr. Robert Lipshutz's employer, Daniel H. Wagner Associates, to Affymax/Affymetrix, holding that the 1991 Wagner–Affymax consulting agreement's Section 2 ("shall be the exclusive property of ARI") effected a present assignment of future rights and that the invention was conceived "in connection with the work scope." Judge Farnan denied the motion. (This ruling has since been cited in later § 261 automatic-assignment cases, e.g., Omni Medsci v. Apple.)
• 2006-07-14: Deadline for summary judgment motions — both parties filed; the court later stayed or denied all such motions. (Illumina 10-Q Q1 2008.)

4. Claim construction (Markman) — 2006-08-16

Decision: Affymetrix, Inc. v. Illumina, Inc., 446 F. Supp. 2d 277 (D. Del. 2006) (Farnan, J.), memorandum opinion and order construing 15 disputed terms/phrases across the five patents-in-suit.

• Affymetrix largely prevailed on the terms that mattered for infringement scope. Per Affymetrix's 2006-08-17 press release, the court rejected Illumina's primary limitations:
  • the patents are not limited to in situ synthesis;
  • are not limited to probes chemically linked to a single surface (the court refused to import a chemical-linkage limitation from a preferred embodiment; "biological polymers immobilized on a surface" = "two or more surface-immobilized biological polymers that are recognized by a particular target");
  • are not limited to probes placed at predetermined locations (thus reaching random bead assembly);
  • "target specific sequence" = "a known polymer sequence that has affinity for another sequence" (rejecting Illumina's narrower "target at the sequence to be determined" construction);
  • "housing" = "a structure that covers, protects, and supports the probe array" (rejecting Illumina's "separates the probe array from the atmosphere").
• The one significant loss for Affymetrix: for the '432 patent, the court adopted Illumina's construction of "said beads being coded with an encoding system" = "said beads having a property associated with each bead (separate from the binding polymer) that can be used to distinguish one bead from another" — i.e., the binding polymer itself cannot serve as the encoding system. Analysts at the time (and academic case studies of the dispute) viewed this as potentially putting some Illumina products outside the '432 claim.
• Post-ruling spin diverged sharply: Illumina said the opinion "construed several key claim terms in our favor" and that its invalidity/unenforceability defenses "were strengthened by the Court's August 2006 rulings"; Affymetrix said the ruling "affirms the breadth of Affymetrix' patent portfolio." Analysts leaned toward reading the net effect as pro-Affymetrix on infringement. Also on 2006-08-16, the court separately denied Illumina's standing motion on the '716 patent.

5. Trial scheduling and the multi-phase structure (late 2006 – early 2007)

• 2006-10-16: Original trial date; rescheduled to 2007-03-05 at the request of both parties. (Illumina 10-K.)
• 2006-12/2006–2007: Initial settlement talks reportedly fell through in January 2007 (Duke University case-study of the dispute).
• 2007-02-08: Pretrial conference; the court entered a February 2007 pretrial order establishing a three-phase trial structure:
  • Phase 1 — infringement and damages;
  • Phase 2 — invalidity / unenforceability / inequitable conduct;
  • Phase 3 — Illumina's unfair competition and antitrust counterclaims.

6. Phase 1 trial and verdict (2007-03-05 to 2007-03-13)

• 2007-03-05: Phase 1 trial began in Wilmington before Judge Farnan. The jury reached a decision within about a day.
• 2007-03-12/13 (verdict; announced 2007-03-13):
  • Jury found Illumina infringed and induced infringement of one or more claims of all five asserted patents ('531, '716, '432, '365, '243) — reported as 12 of the 15 claims at issue.
  • Accused products: Illumina arrays, scanners, software, and related products using BeadArray technology (Array Matrix, BeadChip).
  • Damages: jury rejected Affymetrix's lost-profits claim (Affymetrix had sought $24.2M in lost profits plus $12.2M under a 12% royalty) and instead set a 15% reasonable royalty, awarding approximately $16.7M for sales 2002–2005.
  • The verdict expressly did not address validity or enforceability; willfulness, enhanced damages, attorney's fees, pre-judgment interest, post-2005 sales, and injunctive relief were all deferred.
• Reaction: Illumina (CEO Jay Flatley) called the verdict "very unfortunate" and "preliminary," said it would appeal, and noted no damages would be payable until appeals were exhausted; it vowed to press invalidity, inequitable conduct, and antitrust in phases 2 and 3, predicting resolution "sometime in the middle of 2008." Affymetrix called the verdict a validation of its portfolio and licensing program.

7. Post-trial and Phase 2 posture (mid–late 2007)

• Post-trial motions: Illumina publicly stated the verdict "remains subject to our post-trial motions and appeals." I could not confirm from the sources reached whether a JMOL/new-trial motion was formally ruled on; no judgment was ever entered on the Phase 1 verdict, and Illumina's 10-Q stated it did not expect judgment plus final damages to be entered until after the subsequent phases. No fee motion or injunction ruling was ever reached.
• Phase 2 (validity of the five patents) was scheduled to begin 2008-02-11 — it never convened.
• 2007-10 (late October 2007): second wave of suits. Affymetrix filed three new actions — in the D. Del. (a new case), the Regional Court in Düsseldorf, Germany, and the High Court of Justice, Chancery Division (Patents Court), London — asserting five additional U.S. patents plus three European patents, and targeting all Illumina BeadArray products as well as the Solexa genome-analysis/sequencing technology Illumina acquired in January 2007. Affymetrix's CEO, Dr. Stephen Fodor, framed this as covering Illumina products and markets not addressed in Delaware; commentators (e.g., Foley Hoag's DeAnn Smith) read it as leverage to force a global settlement — and noted concerns that KSR v. Teleflex (2007-04-30) made Affymetrix's patents more vulnerable to obviousness attack.
• 2007-12 / 2008-01: The USPTO granted/ordered reexamination of four of the five asserted Affymetrix patents at Illumina's request (Illumina announced in December 2007 that the Office would begin reexaminations), a development widely viewed as settlement pressure on Affymetrix.

8. Settlement and final disposition (2008-01)

• 2008-01-09 (agreement date; announced 2008-01-10): Global settlement. Illumina Form 8-K filed 2008-01-09; joint press release 2008-01-10. Terms:
  • Illumina pays Affymetrix a one-time $90 million, without admitting liability (paid 2008-01-25; Illumina allocated $36M to a "licensed technology" intangible and expensed $54M in Q4 2007).
  • Affymetrix dismisses with prejudice all lawsuits it brought against Illumina; Illumina dismisses with prejudice its counterclaims.
  • Affymetrix grants Illumina, its affiliates, and its customers a perpetual covenant not to sue for making, using, or selling Illumina's current products, evolutions of those products, and related services; plus a four-year covenant not to sue covering products/services based on future technology developments (running ostensibly to ~2012).
  • Covenant covers all fields except photolithography — Affymetrix's array-manufacturing process, a field in which Illumina did not operate.
  • The settlement resolved the Delaware, Düsseldorf, and UK actions collectively, with payment contingent on formal dismissal by the courts.
• 2008-01-16: Stipulated order of dismissal with prejudice entered; the case was terminated. No judgment on the $16.7M verdict, no injunction, no willfulness/enhanced-damages ruling, no fee award, and no appeal — Illumina's anticipated appeal was mooted.
• Effect on the reexaminations: The USPTO reexaminations of the four Affymetrix patents continued despite the settlement (Illumina confirmed they were not part of the dismissal), and Illumina's spokesperson stressed that the covenant not to sue was one-way — "It does not say that Illumina cannot initiate litigation against Affy." (GenomeWeb, January 2008.)
• Market read: Illumina shares rose ~25% on the news and were upgraded by Lehman Brothers, UBS, and GARP, one GARP analyst calling it a "striking victory" for Illumina and a "defeat" for Affymetrix; Affymetrix shares initially fell ~8%. Affymetrix said it would deploy the $90M for R&D and acquisitions.

9. Parallel PTAB / IPR-PGR proceedings — none; not applicable

This is an important negative finding: there were no IPR or PGR proceedings on the asserted patents, and there could not have been. The Leahy–Smith America Invents Act created IPR, PGR, and CBM review effective 2012-09-16, more than four years after this case terminated (2008-01-16). The parallel administrative challenges in this dispute were instead:

1. USPTO reexaminations — requested by Illumina beginning October 2005 and ordered/granted for four of the five asserted patents around December 2007–January 2008; these outlived the litigation and were expressly noted as continuing after settlement. (Note: whether these were ex parte or inter partes reexaminations is not confirmed in the sources I reached; the contemporaneous reporting describes them generically as "patent re-examinations … filed with … the USPTO.")
2. A separate patent interference declared in March 2007 between an Illumina patent application and US 6,858,412 ("Direct multiplex characterization of genomic DNA"), a Stanford University patent exclusively licensed to Affymetrix's ParAllele Bioscience business — with Illumina named senior party. This was a distinct proceeding and not on the patents-in-suit, but it was part of the same commercial conflict.
3. Illumina's own public statements that it was "engaged in other proceedings against Affymetrix both at the U.S. and European Patent Offices."

If you need a post-2012 PTAB angle, it does not exist for this docket — any modern IPR activity would relate to later-generation Affymetrix/Illumina patents (and the successor litigation between these parties), not to the six patents here.

---

Key sources

• Markman opinion/order: Affymetrix, Inc. v. Illumina, Inc., 446 F. Supp. 2d 277 (D. Del. 2006) (Aug. 16, 2006) — https://www.courtlistener.com/opinion/[2315392](/patent/2315392)/affymetrix-inc-v-illumina-inc/ ; PDF: https://ipmall.info/sites/default/files/hosted_resources/Markman/pdfFiles/2006.08.16_1_AFFYMETRIX_INC_v._ILLUMINA.pdf
• Standing ruling on '716: Affymetrix, Inc. v. Illumina, Inc., 446 F. Supp. 2d 292 (D. Del. 2006) (Aug. 16, 2006) — https://case-law.vlex.com/vid/affymetrix-inc-v-illumina-893321614
• Affymetrix press release, verdict and Markman — 2007-03-13; 2006-08-17 (Business Wire, via BioSpace/demonstratives.com)
• Illumina press release, verdict — 2007-03-13 (Silicon Investor mirror)
• Illumina SEC Form 10-K FY2006 and Form 10-Q Q1 2008 (litigation disclosure; docket milestones 2006-02-15, 2006-06-30, 2006-08-16, 2007-03-13, multi-phase structure, post-trial posture, $90M allocation) — https://www.sec.gov/Archives/edgar/data/[1110803](/patent/1110803)/000093639207000158/a27675e10vk.htm
• Docket items: D.I. 1 (complaint); D.I. 41 (Notice of Service, 2005-03-10); D.I. 205 (Affymetrix letter re Markman scheduling, 2006-02-06); D.I. 234 (motion to dismiss '716 count)
• Settlement: joint press release, 2008-01-10 — https://investor.illumina.com/news/press-release-details/2008/Affymetrix-and-Illumina-Settle-Their-Patent-Disputes/ ; Illumina Form 8-K (2008-01-09)
• GenomeWeb/BioArray News: 2007-03-20 (verdict & Multi-phase), 2008-01 (settlement, reexams continuing, market reaction)
• Drug Discovery News, "Signed, settled, delivered" (settlement terms and reexam motivation) and "North vs. South" (Nov. 2007, second-wave suits)
• Instrument Business Outlook, 2007-03 (verdict; interference)

Caveats — items I could not verify

• The exact complaint filing date (reported only as "July 2004") and the exact verdict date (March 12 vs. March 13, 2007 — press releases are dated March 13; one GenomeWeb piece says "March 12 verdict").
• The identity of the sixth patent dropped in March/June 2006 (I infer '887 from the case metadata but did not confirm).
• The subject of the 2005-07-28 D. Del. opinion listed on the court's own opinion index.
• The precise disposition of Illumina's post-trial motions (JMOL/new trial) — none appears to have been ruled on before dismissal; no judgment was entered.
• Whether the reexamination requests were ex parte vs. inter partes, and the final outcomes of the four reexaminations after settlement.

I'll research the counsel of record for Affymetrix in this case.

Let me gather more detail on the specific attorneys and firms.

Let me verify a few details about additional counsel and the firms involved.

Counsel of Record for Plaintiff Affymetrix, Inc.

Affymetrix, Inc. v. Illumina, Inc., No. 1:04-cv-00901-JJF (D. Del.)

A structural note up front: Affymetrix litigated this case with a hybrid in-house/outside model — an internal trial team housed in Emeryville, California (deliberately walled off from the company's Santa Clara legal department to protect privilege) working with a Wilmington firm as Delaware local counsel. That staffing choice was widely covered at the time and is confirmed in the docket signature blocks and in a sworn declaration filed in a later PTAB proceeding.

Sourcing caveat: I could not query PACER directly in this session. The below is reconstructed from (a) publicly mirrored docket documents on this case, (b) a contemporaneous IP Law & Business article (Dec. 2004), (c) a declaration by Affymetrix in-house attorney George Yu filed in IPR2019-00164 (Ex. 1105, June 2019), and (d) a Law.com feature on Affymetrix's in-house litigation unit. I have flagged anywhere I am inferring rather than confirming.

---

Delaware Local Counsel — Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)

Firm office: 1201 N. Market Street, Wilmington, DE.

---

In-House Counsel — Affymetrix, Inc., Litigation Unit (Emeryville, CA)

These lawyers signed as "OF COUNSEL" on Affymetrix's Delaware filings and, per the IPR declaration, functioned as the de facto trial team.

---

Supervising In-House Executive (not counsel of record)

• Barbara Caulfield — Executive Vice President & General Counsel, Affymetrix. Architect of the in-house litigation model; not listed on Delaware filings. Former IP litigation partner at Latham & Watkins and Orrick, Herrington & Sutcliffe, and a former U.S. District Judge (N.D. Cal., 1991–1995). Relevant as the attorney who directed plaintiff-side strategy.

---

Items I could not verify / explicit gaps

• Formal notice-of-appearance entry numbers and dates. PACER was not directly accessible, so I cannot give you DE numbers for each attorney's appearance. The names above are drawn from signed filings (e.g., D.I. 224, D.I. 286, D.I. 385, D.I. 406, and the Jan. 16, 2008 stipulated dismissal at D.I. 471-2).
• Foley & Lardner LLP. A 2007 stipulated protective order (D.I. 470, filed Aug. 15, 2007) lists "Foley & Lardner LLP" among "Authorized Counsel," but I could not confirm which side it represented or in what capacity. Do not treat it as Affymetrix counsel without further verification.
• Philip McGarrigle — Affymetrix Chief IP Counsel — appears in the record as a fact witness (relevant to prosecution of the '243 patent), not as counsel of record.
• No sealed-counsel issue identified. I found no indication that plaintiff's counsel identity was sealed; the dismissal and protective orders were public.

Bottom line: Affymetrix's plaintiff-side team was Morris, Nichols, Arsht & Tunnell LLP (Jack B. Blumenfeld and Maryellen Noreika, with Derek J. Fahnestock) as Delaware local counsel, working with Affymetrix's in-house litigation unit led by Michael J. Malecek and also comprising Daniel R. Reed, Andrea L. Gross, George C. Yu, Stephen C. Holmes, and Peter E. Root.

I'll research Illumina's defense team in this case, building on the plaintiff-side section already completed.

Strong initial results. Let me verify the local counsel firm transition (Blank Rome → Morris James) and identify the full Kirkland trial team.

Excellent — the F. Supp. 2d opinions confirm the defense team. Let me pin down the local-counsel transition, the trial-era team, and Illumina's in-house counsel.

Counsel of Record for Defendant Illumina, Inc.

Affymetrix, Inc. v. Illumina, Inc., No. 1:04-cv-00901-JJF (D. Del.)

Sourcing note: I could not query PACER directly, and I hit my research-step limit before exhausting every angle (specifically, I could not confirm the exact date of the local-counsel firm transition, verify the roles of a few trade-press–only names, or run down the "Foley & Lardner" line item). The core roster below is grounded in the two published F. Supp. 2d opinions from August 16, 2006 (the Markman opinion, 446 F. Supp. 2d 277, and the standing opinion, 446 F. Supp. 2d 292), which both include official counsel listings, plus signed docket documents mirrored publicly. Facts I am inferring are flagged.

---

Delaware Local Counsel — Morris, James, Hitchens & Williams LLP (later Morris James LLP), Wilmington, DE

Transition caveat: The Dec. 2004 IP Law & Business counsel roster (reprinted on Kirkland's site) listed Blank Rome as Illumina's local counsel with "Richard Hermann." The docket and opinions, however, uniformly show Morris James (Morris, James, Hitchens & Williams). Herrmann practiced at Blank Rome Comisky & McCauley earlier in his career (confirmed by his appearance as plaintiff's counsel in Oxford Gene Technology v. Affymetrix), so the most likely explanation is a firm move by Herrmann around the time of the article, but I could not verify the exact date of the Blank Rome → Morris James transition or whether Blank Rome itself ever entered an appearance in this case. Treat the 2004 "Blank Rome" label as unconfirmed.

---

Lead / Trial Counsel — Kirkland & Ellis LLP

Kirkland carried the substantive defense; its attorneys were admitted pro hac vice and did the heavy lifting at the March 2007 Phase 1 trial. The Aug. 16, 2006 opinions list the appearance team as Krupka, Pals, Sernel, Tang, and Herrmann.

Note: The three associates (Duh, Olson, Wang) appear only in the trade-press roster, not in the opinion counsel listings or in filings I reviewed — plausible for associates, but I could not independently confirm their continued involvement past 2004.

---

In-House Counsel — Illumina, Inc. (San Diego, CA)

Related-but-unconfirmed: Robin Silva, an Illumina patent attorney involved in prosecuting Illumina's BeadArray patents (e.g., the '027/'394/'274/'732 patents), surfaces in the parallel Czarnik v. Illumina inventorship litigation (D. Del. 1:05-cv-00400-JJF). She was a prosecution-side attorney and appears as a witness there; I could not confirm she had any role as counsel in Affymetrix v. Illumina.

---

Items I could not verify / explicit gaps

• "Foley & Lardner LLP" — unresolved. The Aug. 15, 2007 amended protective order (D.I. 440, which Herrmann signed for Illumina) lists five "Authorized Counsel": (i) Morris Nichols; (ii) the Affymetrix Litigation Unit; (iii) Morris James; (iv) Kirkland & Ellis; (v) Foley & Lardner LLP. The Illumina side is plainly Morris James + Kirkland; the Affymetrix side is plainly Morris Nichols + its in-house unit. Foley & Lardner is the outlier, and I could not determine which party it represented or in what capacity. Do not attribute it to Illumina without further verification. (This resolves the same open question flagged in the plaintiff-side section — it remains open.)
• Formal notice-of-appearance DE numbers and dates. PACER was not directly accessible; I cannot give per-attorney appearance entries. Names are drawn from signed filings (D.I. 202, 283, 387, 411, 440) and the two F. Supp. 2d opinion counsel listings.
• Appellate counsel. Illumina signaled an appeal after the March 2007 verdict, but the case settled (Jan. 10, 2008) before any Federal Circuit appeal matured, so no appellate counsel of record exists for this case. (Kirkland would presumably have handled it had the case proceeded.)
• Local counsel for the related 2007 wave (the October 2007 U.S./UK/Germany suits that settled alongside this case) may have differed, but that is outside this docket.

Bottom line: Illumina was defended by Kirkland & Ellis LLP — led by Robert G. Krupka (Los Angeles) and Mark A. Pals (Chicago), with Marcus E. Sernel (Chicago) and Terry L. Tang (San Francisco) — working with Wilmington local counsel Richard K. Herrmann and Mary B. Matterer of Morris, James, Hitchens & Williams LLP / Morris James LLP. Illumina's in-house IP lead was Noemi Espinosa. One firm named in the Dec. 2004 trade-press roster as local counsel, Blank Rome, does not match the docket (which shows Morris James throughout), and Foley & Lardner appears in the protective order without a confirmable side or role.